she woke up with facial paralysis and was diagnosed with Bell's Palsy; she woke up with facial paralysis and was diagnosed with Bell's Palsy; headaches; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the parent.  A 63-year-old female patient received BNT162b2 (BNT162B2), on 09Apr2022 as dose 3 (booster), single (Lot number: FP4554) at the age of 63 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "Diabetic" (unspecified if ongoing); "high blood pressure" (unspecified if ongoing); "Hypothyroidism" (unspecified if ongoing). Concomitant medication(s) included: LOSARTAN taken for hypertension; LEVOTHYROXINE [LEVOTHYROXINE SODIUM] taken for hypothyroidism; METFORMIN taken for diabetes mellitus. Vaccination history included: Bnt162b2 (dose: 1), for COVID-19 Immunization; Bnt162b2 (dose: 2), for COVID-19 Immunization. The following information was reported: HEADACHE (non-serious) with onset 10Apr2022, outcome "recovered" (13Apr2022), described as "headaches"; FACIAL PARALYSIS (medically significant) with onset 10Apr2022, outcome "unknown", BELL'S PALSY (medically significant) with onset 14Apr2022, outcome "not recovered" and all described as "she woke up with facial paralysis and was diagnosed with Bell's Palsy". The events "she woke up with facial paralysis and was diagnosed with bell's palsy" and "headaches" required emergency room visit. The patient underwent the following laboratory tests and procedures: Blood test: (Apr2022) normal, notes: They did blood work and everything was normal. Therapeutic measures were taken as a result of headache.  Clinical course:  The patient's daughter who received the first booster (third dose) of the Pfizer COVID-19 vaccine on April2022 in the evening, shortly after she began experiencing headaches and today in the morning she woke up with facial paralysis and was diagnosed with Bell's Palsy. The patient had to be taken to the emergency room and is currently under observation waiting for her condition to improve, her condition could be more delicate in the future. Throughout the safety follow-up period to date, Bell's palsy (facial paralysis) was reported by 4 participants in the Pfizer-BioNTech COVID-19 Vaccine group. Onset of facial paralysis was Day 37 after Dose 1 (participant did not receive Dose 2) and Days 3, 9, and 48 after Dose 2. 2 Reports in the placebo group. Safety reports do not have more value depending on the reporter as long they have the minimum information required for processing. The third dose of the Pfizer COVID vaccine, this past Saturday 09Apr2022. the patient had headaches but the caller didn't pay attention to it because she knows its common. This morning the patient woke up with a problem with her face there's paralysis and took her to urgent care and referred her to the emergency room. The patient was diagnosed with Bell's Palsy. The caller was reading and asked doctors about this, there is not enough data. The providers suspect this is from the vaccine. The caller read some studies that there are the same problem reported. The patient took some medicine for her headache and it was a little better but lasted for 3 days. At 8:30 am the patient told the caller about the Bells Palsy.   No follow-up attempts are possible. No further information is expected.